{"component": "definition", "props": {"groups": [{"samples": [{"hash": "dv1QK7B0aWi", "uri": "/contracts/dv1QK7B0aWi#co-development", "label": "Collaboration and License Agreement (Facet Biotech Corp)", "score": 21.2847366333, "published": true}, {"hash": "dFAuIortDj4", "uri": "/contracts/dFAuIortDj4#co-development", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.2108154297, "published": true}, {"hash": "fXtvZWd168N", "uri": "/contracts/fXtvZWd168N#co-development", "label": "Collaboration and License Agreement (Trubion Pharmaceuticals, Inc)", "score": 21.0, "published": true}], "snippet": "means the joint Development of a Collaboration Product in the Field, in the Territory by both Parties under the terms of this Agreement. \u201cCo-Develop,\u201d when used as a verb, means to engage in such Co-Development.", "size": 4, "snippet_links": [{"key": "development-of-a", "type": "clause", "offset": [16, 32]}, {"key": "collaboration-product", "type": "clause", "offset": [33, 54]}, {"key": "in-the-field", "type": "clause", "offset": [55, 67]}, {"key": "in-the-territory", "type": "clause", "offset": [69, 85]}, {"key": "by-both-parties", "type": "clause", "offset": [86, 101]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [112, 135]}], "hash": "10aa63c5347c939b63ebcf08b7873b5e", "id": 1}, {"samples": [{"hash": "2UN3ciuaAyX", "uri": "/contracts/2UN3ciuaAyX#co-development", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "eLXwMP3BD51", "uri": "/contracts/eLXwMP3BD51#co-development", "label": "Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "2m22LWPasd4", "uri": "https://newsroom.regeneron.com/static-files/891ddb6b-cc23-4269-a58c-8279f792bb53", "label": "newsroom.regeneron.com", "score": 9.965092659, "published": false}], "snippet": "means the joint Development of VEGF Products by the Parties, as described herein, and \u201cCo-Develop\u201d shall have a corresponding meaning.", "size": 4, "snippet_links": [{"key": "development-of", "type": "clause", "offset": [16, 30]}, {"key": "vegf-products", "type": "definition", "offset": [31, 44]}, {"key": "by-the-parties", "type": "clause", "offset": [45, 59]}], "hash": "91dc6503df5cc43b7fd41dfa739e4d8a", "id": 2}, {"samples": [{"hash": "cYUZxBYsBNb", "uri": "/contracts/cYUZxBYsBNb#co-development", "label": "Collaboration, License and Option Agreement (Regeneron Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "hSkaWFDEIYC", "uri": "https://regeneronpharmaceuticalsinc.gcs-web.com/static-files/105b312c-45b1-4bdd-b1c1-a91a0b09c338", "label": "regeneronpharmaceuticalsinc.gcs-web.com", "score": 12.9284374559, "published": false}, {"hash": "hSkaWFDEIYC", "uri": "https://newsroom.regeneron.com/index.php/static-files/105b312c-45b1-4bdd-b1c1-a91a0b09c338", "label": "newsroom.regeneron.com", "score": 7.9650921822, "published": false}], "snippet": "means the joint Development of IL-1 Products by the Parties, as described in Sections 5.5 to 5.8 inclusive, following: (a) the Effective Date with respect to Trap-1 Products; (b) the proper exercise of the IL-1 Antibody Opt-In Rights, with respect to IL-1 Antibody Products; and (c) the proper exercise of the Trap-2 Opt-In Rights, with respect to Trap-2 Products, and \"Co-Develop\" shall have a corresponding meaning.", "size": 3, "snippet_links": [{"key": "development-of", "type": "clause", "offset": [16, 30]}, {"key": "by-the-parties", "type": "clause", "offset": [45, 59]}, {"key": "the-effective-date", "type": "clause", "offset": [123, 141]}, {"key": "with-respect-to", "type": "clause", "offset": [142, 157]}, {"key": "exercise-of-the", "type": "clause", "offset": [190, 205]}, {"key": "il-1-antibody", "type": "definition", "offset": [206, 219]}, {"key": "in-rights", "type": "clause", "offset": [224, 233]}], "hash": "5712eef8e403cd337d0e10f3878c3df3", "id": 3}, {"samples": [{"hash": "eAVhda9aWIa", "uri": "/contracts/eAVhda9aWIa#co-development", "label": "Collaborative Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "cZunLh8FFTC", "uri": "/contracts/cZunLh8FFTC#co-development", "label": "Collaborative Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}], "snippet": "means Development of a Co-Developed Product after ARCHEMIX\u2019 exercise of a Co-Development Option as described in Section 4.11.1.", "size": 2, "snippet_links": [{"key": "development-of-a", "type": "clause", "offset": [6, 22]}, {"key": "developed-product", "type": "definition", "offset": [26, 43]}, {"key": "exercise-of", "type": "clause", "offset": [60, 71]}, {"key": "development-option", "type": "definition", "offset": [77, 95]}], "hash": "9b6ba38394d828bca84e04249fc8b249", "id": 4}, {"samples": [{"hash": "kDmXL7lKWwL", "uri": "/contracts/kDmXL7lKWwL#co-development", "label": "Development Agreement (BioNTech SE)", "score": 30.6865158081, "published": true}, {"hash": "hZLX1XmEI3M", "uri": "/contracts/hZLX1XmEI3M#co-development", "label": "Development Agreement (BioNTech SE)", "score": 30.5906906128, "published": true}], "snippet": "Report is defined in Section 2.5.", "size": 2, "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [10, 28]}], "hash": "db79a9554db44f6834cdb092181eb13f", "id": 5}, {"samples": [{"hash": "19UoJlVtoI2", "uri": "/contracts/19UoJlVtoI2#co-development", "label": "License and Affiliation Agreement", "score": 32.3053283691, "published": true}, {"hash": "2Jc9hLCqzv3", "uri": "/contracts/2Jc9hLCqzv3#co-development", "label": "License and Affiliation Agreement", "score": 32.1903572083, "published": true}], "snippet": "Licensor and Licensee shall use their best efforts to collaborate, through dialogue, communication, interaction and mutual support, in co-developing and continually improving the Schools and their operations, curriculum, environment, facilities, communities and educational experience and outcomes, all in furtherance of the CWC Network Fundamentals (the \u201cCo- Development Goals\u201d).", "size": 2, "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [13, 27]}, {"key": "best-efforts", "type": "clause", "offset": [38, 50]}, {"key": "mutual-support", "type": "definition", "offset": [116, 130]}, {"key": "the-schools", "type": "clause", "offset": [175, 186]}, {"key": "educational-experience", "type": "clause", "offset": [262, 284]}, {"key": "development-goals", "type": "clause", "offset": [360, 377]}], "hash": "26abb404549dd3beb7611929614ae419", "id": 6}, {"samples": [{"hash": "8lliXhMw1im", "uri": "/contracts/8lliXhMw1im#co-development", "label": "Co Development and Supply Agreement (Comverge, Inc.)", "score": 21.0, "published": true}, {"hash": "gsl6qrMlYB5", "uri": "/contracts/gsl6qrMlYB5#co-development", "label": "Co Development and Supply Agreement (Comverge, Inc.)", "score": 19.0, "published": true}], "snippet": "means the activities between the Parties targeted at integrating the Customized Thermostat, to be developed by WR, with the Communications Module, to be developed by Comverge, pursuant to a particular Statement of Work.", "size": 2, "snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "between-the-parties", "type": "clause", "offset": [21, 40]}, {"key": "communications-module", "type": "definition", "offset": [124, 145]}, {"key": "pursuant-to-a", "type": "definition", "offset": [176, 189]}, {"key": "statement-of-work", "type": "definition", "offset": [201, 218]}], "hash": "6f32da19a611169f901cb41c4818f7aa", "id": 7}, {"samples": [{"hash": "kcqCkX7M5ZH", "uri": "/contracts/kcqCkX7M5ZH#co-development", "label": "Co Development Agreement (Fireman B.V.)", "score": 28.8494186401, "published": true}, {"hash": "4mQ74w2gblX", "uri": "/contracts/4mQ74w2gblX#co-development", "label": "Co Development Agreement (Fireman B.V.)", "score": 28.7809715271, "published": true}], "snippet": "means any development effort undertaken by either Party in order to fulfill the Purpose of this Agreement and as set forth in the Frame of Co-Development (as defined below).", "size": 2, "snippet_links": [{"key": "development-effort", "type": "clause", "offset": [10, 28]}, {"key": "by-either-party", "type": "clause", "offset": [40, 55]}, {"key": "in-order-to", "type": "clause", "offset": [56, 67]}, {"key": "the-purpose-of-this-agreement", "type": "clause", "offset": [76, 105]}], "hash": "7ad26ced821ce731152ce09b66102e82", "id": 8}, {"samples": [{"hash": "4ZouCrOC06i", "uri": "/contracts/4ZouCrOC06i#co-development", "label": "Basic Contract on Joint Development and Grant of License (Magnachip Semiconductor LLC)", "score": 21.1998634338, "published": true}, {"hash": "egKqiOBPHdm", "uri": "/contracts/egKqiOBPHdm#co-development", "label": "Joint Development and License Agreement (Magnachip Semiconductor LLC)", "score": 21.0, "published": true}], "snippet": "means a series of development activities for which SW takes the responsibility of design for the Contract Product, MC manufactures it, SW and MC jointly validate characteristics of the products and MC completes the development in accordance with the rule on new product introduction (\u201cNPI,\u201d hereinafter).", "size": 2, "snippet_links": [{"key": "development-activities", "type": "clause", "offset": [18, 40]}, {"key": "responsibility-of", "type": "clause", "offset": [64, 81]}, {"key": "the-contract", "type": "clause", "offset": [93, 105]}, {"key": "the-products", "type": "clause", "offset": [181, 193]}, {"key": "the-development", "type": "clause", "offset": [211, 226]}, {"key": "in-accordance-with", "type": "clause", "offset": [227, 245]}, {"key": "the-rule", "type": "clause", "offset": [246, 254]}, {"key": "new-product-introduction", "type": "definition", "offset": [258, 282]}], "hash": "a4bd29b873501b060d5b911588208e28", "id": 9}, {"samples": [{"hash": "6r1pgJWB7w1", "uri": "/contracts/6r1pgJWB7w1#co-development", "label": "Collaboration and License Agreement (Guilford Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means, with respect to Guilford's option to co-develop the Co-Development Indication as set forth in Article Six, Guilford's conduct of Phase I and Phase II (but not Phase III) clinical trials in the capacity of a contract clinical research organization, subject to Amgen's approval of sites, investigators, protocols, investigators' brochures, monitoring and data analysis plans, budgets and all other matters not limited to implementation of any of the foregoing.", "size": 1, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "option-to", "type": "clause", "offset": [34, 43]}, {"key": "the-co", "type": "clause", "offset": [55, 61]}, {"key": "development-indication", "type": "definition", "offset": [62, 84]}, {"key": "article-six", "type": "definition", "offset": [101, 112]}, {"key": "conduct-of", "type": "clause", "offset": [125, 135]}, {"key": "phase-i-and-phase-ii", "type": "clause", "offset": [136, 156]}, {"key": "phase-iii", "type": "clause", "offset": [166, 175]}, {"key": "clinical-trials", "type": "clause", "offset": [177, 192]}, {"key": "clinical-research-organization", "type": "definition", "offset": [223, 253]}, {"key": "to-amgen", "type": "clause", "offset": [263, 271]}, {"key": "approval-of", "type": "definition", "offset": [274, 285]}, {"key": "data-analysis", "type": "definition", "offset": [360, 373]}, {"key": "all-other-matters", "type": "clause", "offset": [393, 410]}, {"key": "not-limited", "type": "clause", "offset": [411, 422]}, {"key": "the-foregoing", "type": "definition", "offset": [451, 464]}], "hash": "a841833684e2d9488899a31ed88cf9ea", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXY28tZGV2ZWxvcG1lbnQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means the joint Development of a Collaboration Product in the Field, in the Territory by both Parties under the terms of this Agreement. \u201cCo-Develop,\u201d when used as a verb, means to engage in such Co-Development.", "size": 29, "title": "Co-Development", "id": "co-development", "examples": ["<strong>Co-Development</strong> and Distribution Agreement between SurgiVision, Inc.", "Within forty-five (45) days following the end of the Calendar Quarter, the JSC shall submit to the Parties a written report setting forth in reasonable detail (c) the calculation of Operating Income, determined in accordance with Schedule 6 attached hereto and (d) the calculation of the amount of Operating Income payable to Enanta in accordance with the Enanta <strong>Co-Development</strong> Percentage for that Co-Developed Product taking into account Enanta\u2019s expenditures for the period.", "Unless otherwise specified in a <strong>Co-Development</strong> Plan and Budget amounts reflected for a full year shall be deemed budgeted in equal amounts for each calendar quarter of such year.", "Each such further elaborated and refined <strong>Co-Development</strong> Plan shall be deemed a part of, and is hereby incorporated by reference in, this Agreement.", "An itemized account of the Projected Cost including person-year rates applied as Alliance, Technology and/or <strong>Co-Development</strong> Rates as defined in the GLA is set forth in Exhibit 2 attached hereto.", "The responsibilities of the JDC shall consist of (i) overseeing the ongoing development of Co-Funded Product(s), (ii) establishing <strong>Co-Development</strong> Plans and Budgets for Co-Funded Products, (iii) monitoring and approving development activities under such <strong>Co-Development</strong> Plans and Budgets, (iv) reviewing and approving regulatory correspondence, final study reports and submissions to Regulatory Authorities relating to Co-Funded Products, and (v) making such decisions as are expressly provided in Article 3.", "Enanta shall receive from \u2587\u2587\u2587\u2587\u2587\u2587, in lieu of receiving any Royalty Payments with respect to each Co-Developed Product in the <strong>Co-Development</strong> Territory, the Enanta <strong>Co-Development</strong> Percentage of all Annual Operating Income derived from sales of that Co-Developed Product in the <strong>Co-Development</strong> Territory (such payments, the \u201cOperating Income Payments\u201d) for as long as there are sales by \u2587\u2587\u2587\u2587\u2587\u2587, its Affiliates and Sublicensees of such Co-Developed Product (the \u201c<strong>Co-Development</strong> Term\u201d).", "As soon as practicable following the exercise by Enanta of a <strong>Co-Development</strong> and Profit-Share Option with respect to a Compound or Candidate, as the case may be, in accordance with Section 5.1, Enanta and \u2587\u2587\u2587\u2587\u2587\u2587 shall establish the Joint <strong>Co-Development</strong> and Commercialization Committee which shall have and perform the responsibilities set forth in Section 2.3.4.", "On and after the date of exercise by Enanta of its <strong>Co-Development</strong> and Profit Share Option for a Co-Developed Product and continuing for the Term of this Agreement [*****], whichever date is earlier, each Party shall provide written notice to the other Party to the extent it Materially Used any Shared Clinical Trial Data (the \u201cShared Clinical Trial Notice\u201d).", "Upon Sunesis\u2019 exercise of the Co-Funding Option, the Parties shall form a product team with respect to each Co-Funded Product that shall report to the JDC, comprised of Biogen Idec and Sunesis personnel that will implement the further development and regulatory affairs with respect to that Co-Funded Product (each a \u201cProduct Team\u201d) in accordance with the <strong>Co-Development</strong> Plan and Budget."], "related": [["infill-development", "Infill development", "Infill development"], ["economic-development", "Economic development", "Economic development"], ["experimental-development", "experimental development", "experimental development"], ["research-and-development", "Research and development", "Research and development"], ["planned-development", "Planned development", "Planned development"]], "related_snippets": [], "updated": "2025-07-24T04:27:56+00:00"}, "json": true, "cursor": ""}}